VIR (Vir Biotechnology, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by VIR officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-12 | ROBERT J MORE | Director | J | — | — |
| 2026-06-10 | Timothy Coughlin | Director | A | — | — |
| 2026-06-02 | Janet Napolitano | Director | Sell | — | — |
| 2026-06-02 | Brent Sabatini | SVP, Chief Accounting Officer | Sell | — | — |
| 2026-05-28 | Jeffrey S. Hatfield | Director | A | — | — |
| 2026-05-28 | NORBERT W BISCHOFBERGER | Director | A | — | — |
| 2026-05-28 | Charles Elliott Sigal | Director | A | — | — |
| 2026-05-28 | Ramy Farid | Director | A | — | — |
| 2026-05-28 | ROBERT J MORE | Director | A | — | — |
| 2026-05-28 | Janet Napolitano | Director | A | — | — |
| 2026-05-04 | VICKI L SATO | Director | Sell | — | — |
| 2026-04-07 | Marianne De Backer | President and CEO | Sell | — | — |
| 2026-04-02 | VICKI L SATO | Director | Sell | — | — |
| 2026-03-24 | Brent Sabatini | SVP, Chief Accounting Officer | Sell | — | — |
| 2026-03-23 | Jason O'Byrne | EVP & Chief Financial Officer | J | — | — |
| 2026-03-03 | VICKI L SATO | Director | Sell | — | — |
| 2026-02-26 | Mark Eisner | EVP and Chief Medical Officer | Sell | — | — |
| 2026-02-26 | Jason O'Byrne | EVP & Chief Financial Officer | Sell | — | — |
| 2026-02-26 | Marianne De Backer | Chief Executive Officer | Sell | — | — |
| 2026-02-26 | VICKI L SATO | Director | MIXED | — | — |
| 2026-02-26 | Brent Sabatini | SVP, Chief Accounting Officer | Sell | — | — |
| 2026-02-26 | Vanina de Verneuil | EVP, General Counsel, Corp Sec | Sell | — | — |
| 2026-02-24 | Brent Sabatini | SVP, Chief Accounting Officer | MIXED | — | — |
| 2026-02-24 | Vanina de Verneuil | EVP, General Counsel, Corp Sec | MIXED | — | — |
| 2026-02-24 | Jason O'Byrne | EVP & Chief Financial Officer | MIXED | — | — |
| 2026-02-24 | Marianne De Backer | Chief Executive Officer | MIXED | — | — |
| 2026-02-24 | Mark Eisner | EVP and Chief Medical Officer | MIXED | — | — |
| 2026-02-18 | Brent Sabatini | SVP, Chief Accounting Officer | Sell | — | — |
| 2026-02-03 | VICKI L SATO | Director | Sell | — | — |
| 2026-01-05 | VICKI L SATO | Director | Sell | — | — |
| 2025-12-03 | SOFTBANK VISION FUND (AIV M1) L.P. | 10%+ Owner | Sell | — | — |
| 2025-12-02 | VICKI L SATO | Director | Sell | — | — |
| 2025-12-01 | SOFTBANK VISION FUND (AIV M1) L.P. | 10%+ Owner | Sell | — | — |
| 2025-11-26 | SOFTBANK VISION FUND (AIV M1) L.P. | 10%+ Owner | Sell | — | — |
| 2025-11-18 | Jason O'Byrne | EVP & Chief Financial Officer | Sell | — | — |
| 2025-11-07 | Vanina de Verneuil | EVP, General Counsel, Corp Sec | Sell | — | — |
| 2025-11-04 | Vanina de Verneuil | EVP and General Counsel | Sell | — | — |
| 2025-11-04 | VICKI L SATO | Director | Sell | — | — |
| 2025-10-30 | SB INVESTMENT ADVISERS (UK) LTD | 10%+ Owner | Sell | — | — |
| 2025-10-28 | SB INVESTMENT ADVISERS (UK) LTD | 10%+ Owner | Sell | — | — |
| 2025-10-24 | SOFTBANK VISION FUND (AIV M1) L.P. | 10%+ Owner | Sell | — | — |
| 2025-10-22 | SOFTBANK VISION FUND (AIV M1) L.P. | 10%+ Owner | Sell | — | — |
| 2025-10-17 | SB INVESTMENT ADVISERS (UK) LTD | 10%+ Owner | Sell | — | — |
| 2025-10-14 | SB INVESTMENT ADVISERS (UK) LTD | 10%+ Owner | Sell | — | — |
| 2025-10-09 | SOFTBANK VISION FUND (AIV M1) L.P. | 10%+ Owner | Sell | — | — |
| 2025-10-07 | SOFTBANK VISION FUND (AIV M1) L.P. | 10%+ Owner | Sell | — | — |
| 2025-10-02 | VICKI L SATO | Director | Sell | — | — |
| 2025-09-03 | VICKI L SATO | Director | Sell | — | — |
| 2025-08-04 | VICKI L SATO | Director | Sell | — | — |
| 2025-07-17 | Mark Eisner | EVP and Chief Medical Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 14,574,083 | — |
| — | 10%+ Owner | 13,728,924 | — |
| — | Director | 12,111,109 | — |
| — | 10%+ Owner | 11,735,405 | — |
| — | 10%+ Owner | 11,111,112 | — |
| — | 10%+ Owner | 9,276,692 | — |
| — | 10%+ Owner | 8,726,408 | — |
| — | Director | 7,874,803 | — |
| — | 10%+ Owner | 7,563,619 | — |
| — | 10%+ Owner | 3,333,333 | — |
| — | 10%+ Owner | 2,777,777 | — |
| — | — | 2,666,666 | — |
| — | Director | 1,296,509 | — |
| — | — | 1,111,111 | — |
| — | Director | 1,078,391 | — |
| — | President and CEO | 1,001,263 | — |
| — | Director | 558,573 | — |
| — | Director | 440,621 | — |
| — | EVP, Research & CSO | 262,500 | — |
| — | EVP & Chief Medical Officer | 250,111 | — |
| — | CFO | 230,712 | — |
| — | 10%+ Owner | 208,852 | — |
| — | 10%+ Owner | 173,844 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the VIR quote page; the site-wide leaderboard is on the insider transactions hub.